drugset
drugset / Trial / NCT05841940

Mass Balance Study of [14C]HLX208 in China Healthy Subjects

NCT05841940 ↗

Phase 1 Completed 6 enrolled Shanghai Henlius Biotech
NaSingle-groupOpen-labelOther

Summary

Mass Balance Study of \[14C\]HLX208 in China Healthy Subjects.

Timeline

Start
2023-06-17
Primary completion
2023-07-15
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject HLX208 Unknown 450 mg Oral

Indications

No indication recorded.